Developer docs
API playgroundTry for free, no card

Search company profiles

Plectonic Biotech

Full company profile

uuid0009jwr

Namestring
Plectonic Biotech
Legal namestring
Plectonic Biotech GmbH
Websiteurl
plectonic.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Plectonic Biotech GmbH is a German preclinical-stage biotechnology company headquartered in Hallbergmoos near Munich, founded in 2022–2023 as a spin-off from the Technical University of Munich. The company develops LOGIBODY (LOGIc-gated antiBODies), a DNA nanotechnology-based immunotherapy platform that uses DNA-origami scaffolds as molecular logic gates to activate immune responses only when a specific tumor antigen pattern is detected. LOGIBODYs combine antibody-based targeting with DNA nanostructure stability and modularity, enabling if-then conditional T cell engagement intended to reduce on-target/off-tumor toxicity and uncontrolled cytokine release relative to conventional bispecific antibodies.

The company's product strategy is a preclinical pipeline across two undisclosed oncology indications, with stated optionality to extend LOGIBODY's logic-gated mechanism into autoimmune diseases. Co-founders Dr. Klaus Wagenbauer (CEO), Dr. Jonas Funke (CTO), Dr. Benjamin Kick (COO), and co-founder Prof. Hendrik Dietz bring more than 13 years of DNA nanotechnology expertise from TUM; co-inventor Benjamin Kick has also developed scalable, cost-efficient DNA nanostructure manufacturing methods relevant to industrial supply. The company's intellectual property position includes co-invented LOGIBODY and Ultra-Beacon technologies and multiple granted patents covering therapeutic and diagnostic applications of DNA nanotechnology, with foundational research published in Nature Nanotechnology in 2023.

Plectonic is pre-commercial with no product revenue; non-dilutive grant funding includes the €2.5M m4 Award (BioM, 2019), GO-Bio (BMBF) support, and a multi-year SPRIND commitment announced in 2023. The go-to-market posture is partnership-driven: the company explicitly seeks pharmaceutical and biotech partners for clinical development, manufacturing, and eventual commercialization, while building internal CMC and preclinical capabilities and a 2025 collaboration with Sonrai Analytics for AI-powered antigen discovery. Customers are therefore future enterprise pharma/biotech licensing partners rather than end-patient or provider buyers at this stage.

Short descriptiontext

Plectonic Biotech GmbH is a German preclinical-stage biotech, spun out of the Technical University of Munich, developing LOGIBODY — a DNA-nanotechnology immunotherapy platform using logic-gated antibodies to enable precise, conditional tumor targeting in oncology and autoimmune disease, and seeking pharma partners for clinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA nanotechnology therapeutics, cancer immunotherapy platform, logic-gated antibodies, bispecific T cell engagers, preclinical oncology biotech
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Immunotherapy
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Plectonic Biotech develops the LOGIBODY Technology Platform, a DNA nanotechnology-based immunotherapy platform for targeted cancer therapy. LOGIBODYs are logic-gated antibodies built on DNA nanostructure scaffolds that selectively activate immune cells only when a specific tumor antigen pattern is detected, combining antibody specificity with DNA-based structural stability and modularity. The platform is being advanced through preclinical development for two undisclosed oncology indications with potential expansion into autoimmune disease applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Precise immune activation with reduced side effects demonstrated in Nature Nanotechnology publication (2023)
Product overview1 text field

Plectonic Biotech offers the LOGIBODY Technology Platform as its core product—a DNA-based immunotherapy platform designed for targeted cancer therapy. The platform combines the specificity of antibody-based targeting with the enhanced stability and modularity of DNA nanostructures, implementing a novel logic-gated mechanism that enables precise tumor targeting while reducing off-target effects. LOGIBODYs function as intelligent antibodies that activate selectively at the tumor site, recognizing tumors by their unique antigen patterns rather than single target molecules, and can be flexibly customized to target different cancer types by swapping antibody modules.

Product and service1 record
1LOGIBODY Technology Platform
CategoryCancer Immunotherapy / DNA Nanotechnology Therapeutics
Description

DNA-based immunotherapy platform combining antibody specificity with DNA nanostructure stability and modularity. LOGIBODYs (LOGIc-gated antiBODies) are intelligent antibodies built on a DNA scaffold acting as a molecular switch; they recognize tumors by their unique multi-antigen pattern rather than single targets and only activate immune cells when that pattern is detected, enabling selective, reversible, site-specific T cell engagement. The platform is designed for pharmaceutical and biotech partners for preclinical and clinical development in oncology and autoimmune indications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Strategic collaboration to integrate high-resolution, AI-powered antigen discovery into LOGIBODY technology development. Aims to drive safer, more targeted cancer immunotherapies through enhanced antigen identification capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic institution from which Plectonic Biotech spun off. Founding research on LOGIBODY technology originated from TUM laboratories. Company maintains close ties with TUM researchers and facilities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Bavarian Biotech Cluster organization supporting biotech innovation. Provided m4 Award funding in 2019 for early research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

European health innovation community providing support and resources for healthcare innovation across Europe.

5Plectonic Logibody GmbH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Affiliated entity executing research on LOGIBODY technology. Company founded as spin-off with research executed through this partner organization.

plectonic.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adagene uses AI-driven antibody discovery and engineering to develop precision antibodies including conditionally activated formats. The company represents a peer in next-generation antibody engineering combining computational approaches with novel antibody architectures, paralleling Plectonic's LOGIBODY + Sonrai AI strategy.

TypeBroad incumbent
Description

Philogen develops antibody-based therapeutics for oncology and inflammatory diseases, including antibody-cytokine fusion proteins and targeted immunocytokines. As a European clinical-stage antibody therapeutics company, Philogen represents both a comparable regional player and a potential strategic partner for Plectonic's T-cell engaging platform.

TypeDirect peer
Description

Numab develops multispecific antibodies using its proprietary lambda-cap and Fv-Ig formats that combine multiple binding specificities in single molecules. Both companies engineer multi-specificity antibody constructs designed to achieve selective biological function through combinatorial antigen recognition.

TypeBroad incumbent
Description

Genmab is the leading independent bispecific antibody company with its Duobody platform, generating products like epcoritamab. As the established leader in bispecific antibody engineering for oncology, Genmab represents both a potential partner and the competitive benchmark that any next-generation bispecific or logic-gated platform must outperform.

TypeDirect peer
Description

BioAtla develops Conditionally Active Biologics (CABs), which are antibodies and other proteins engineered to activate selectively in the tumor microenvironment using a similar logic-gated mechanism to LOGIBODY. Both companies are pursuing the same strategic thesis: that conditional, tumor-restricted activation can overcome the safety ceiling of conventional antibody therapies.

TypeDirect peer
Description

Molecular Partners develops DARPins (Designed Ankyrin Repeat Proteins), a non-antibody scaffold alternative to traditional monoclonal antibodies for therapeutic applications. Both companies engineer novel protein scaffolds as alternatives to conventional antibodies, pursuing similar therapeutic goals through different structural approaches.

TypeDirect peer
Description

Maverick developed logic-gated T-cell engagers designed to activate only when both a tumor antigen and a second contextual marker are detected — directly analogous to Plectonic's LOGIBODY mechanism. Acquired by Takeda in 2021, Maverick represents the most direct mechanistic parallel in oncology immunotherapy.

TypeEmerging player
Description

Cullinan Oncology is a clinical-stage biopharmaceutical company developing a diversified pipeline of oncology therapeutics including T-cell engagers and bispecific antibodies. Both companies pursue multi-program oncology strategies targeting immune engagement with novel modalities, though Cullinan is several years ahead clinically.

TypeDirect peer
Description

CytomX's Probody platform uses conditionally activated antibodies that are masked until activated by tumor-associated proteases — conceptually the closest commercial-stage analogue to Plectonic's logic-gated LOGIBODY approach. Both companies target the same unmet need of reducing on-target/off-tumor toxicity in antibody therapeutics.

TypeDirect peer
Description

Crescendo Biologics develops T-cell engagers based on a proprietary Humabody VH domain platform — a non-standard antibody scaffold for engaging immune cells against tumors. Both companies pursue T-cell-engaging therapeutics using novel protein scaffolds as alternatives to conventional bispecific antibodies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Plectonic Biotech

Cancer Immunotherapyplectonic.com

Plectonic Biotech GmbH is a German preclinical-stage biotech, spun out of the Technical University of Munich, developing LOGIBODY — a DNA-nanotechnology immunotherapy platform using logic-gated antibodies to enable precise, conditional tumor targeting in oncology and autoimmune disease, and seeking pharma partners for clinical development.

What Plectonic Biotech does

Plectonic Biotech GmbH is a German preclinical-stage biotechnology company headquartered in Hallbergmoos near Munich, founded in 2022–2023 as a spin-off from the Technical University of Munich. The company develops LOGIBODY (LOGIc-gated antiBODies), a DNA nanotechnology-based immunotherapy platform that uses DNA-origami scaffolds as molecular logic gates to activate immune responses only when a specific tumor antigen pattern is detected. LOGIBODYs combine antibody-based targeting with DNA nanostructure stability and modularity, enabling if-then conditional T cell engagement intended to reduce on-target/off-tumor toxicity and uncontrolled cytokine release relative to conventional bispecific antibodies.

The company's product strategy is a preclinical pipeline across two undisclosed oncology indications, with stated optionality to extend LOGIBODY's logic-gated mechanism into autoimmune diseases. Co-founders Dr. Klaus Wagenbauer (CEO), Dr. Jonas Funke (CTO), Dr. Benjamin Kick (COO), and co-founder Prof. Hendrik Dietz bring more than 13 years of DNA nanotechnology expertise from TUM; co-inventor Benjamin Kick has also developed scalable, cost-efficient DNA nanostructure manufacturing methods relevant to industrial supply. The company's intellectual property position includes co-invented LOGIBODY and Ultra-Beacon technologies and multiple granted patents covering therapeutic and diagnostic applications of DNA nanotechnology, with foundational research published in Nature Nanotechnology in 2023.

Plectonic is pre-commercial with no product revenue; non-dilutive grant funding includes the €2.5M m4 Award (BioM, 2019), GO-Bio (BMBF) support, and a multi-year SPRIND commitment announced in 2023. The go-to-market posture is partnership-driven: the company explicitly seeks pharmaceutical and biotech partners for clinical development, manufacturing, and eventual commercialization, while building internal CMC and preclinical capabilities and a 2025 collaboration with Sonrai Analytics for AI-powered antigen discovery. Customers are therefore future enterprise pharma/biotech licensing partners rather than end-patient or provider buyers at this stage.

Plectonic Biotech firmographics

Firmographics
Name
Plectonic Biotech
Legal name
Plectonic Biotech GmbH
Website
https://plectonic.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Plectonic Biotech GmbH is a German preclinical-stage biotech, spun out of the Technical University of Munich, developing LOGIBODY — a DNA-nanotechnology immunotherapy platform using logic-gated antibodies to enable precise, conditional tumor targeting in oncology and autoimmune disease, and seeking pharma partners for clinical development.
Ownership category
akta.pro rank

Plectonic Biotech industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • DNA nanotechnology therapeutics
  • Cancer immunotherapy platform
  • Logic-gated antibodies
  • Bispecific T cell engagers
  • Preclinical oncology biotech

Where Plectonic Biotech is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Plectonic Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Plectonic Biotech product offering

Product offering

Core offering

Plectonic Biotech develops the LOGIBODY Technology Platform, a DNA nanotechnology-based immunotherapy platform for targeted cancer therapy. LOGIBODYs are logic-gated antibodies built on DNA nanostructure scaffolds that selectively activate immune cells only when a specific tumor antigen pattern is detected, combining antibody specificity with DNA-based structural stability and modularity. The platform is being advanced through preclinical development for two undisclosed oncology indications with potential expansion into autoimmune disease applications.

Product overview

Plectonic Biotech offers the LOGIBODY Technology Platform as its core product—a DNA-based immunotherapy platform designed for targeted cancer therapy. The platform combines the specificity of antibody-based targeting with the enhanced stability and modularity of DNA nanostructures, implementing a novel logic-gated mechanism that enables precise tumor targeting while reducing off-target effects. LOGIBODYs function as intelligent antibodies that activate selectively at the tumor site, recognizing tumors by their unique antigen patterns rather than single target molecules, and can be flexibly customized to target different cancer types by swapping antibody modules.

Differentiator

Problem solved

Functional benefit

Products and services

  • LOGIBODY Technology Platform DNA-based immunotherapy platform combining antibody specificity with DNA nanostructure stability and modularity. LOGIBODYs (LOGIc-gated antiBODies) are intelligent antibodies built on a DNA scaffold acting as a molecular switch; they recognize tumors by their unique multi-antigen pattern rather than single targets and only activate immune cells when that pattern is detected, enabling selective, reversible, site-specific T cell engagement. The platform is designed for pharmaceutical and biotech partners for preclinical and clinical development in oncology and autoimmune indications.

Quantifiable outcome

  • Precise immune activation with reduced side effects demonstrated in Nature Nanotechnology publication (2023)

Companies that use Plectonic Biotech

Customer profile

Segments2 records

Ideal customer profiles1 record

Plectonic Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Plectonic Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Sonrai AnalyticscoreTechnology or Integration · 1 January 2025Strategic collaboration to integrate high-resolution, AI-powered antigen discovery into LOGIBODY technology development. Aims to drive safer, more targeted cancer immunotherapies through enhanced antigen identification capabilities.
  • TUM (Technical University of Munich)coreStrategic or Co-development PartnerAcademic institution from which Plectonic Biotech spun off. Founding research on LOGIBODY technology originated from TUM laboratories. Company maintains close ties with TUM researchers and facilities.
  • BioMminorStrategic or Co-development PartnerBavarian Biotech Cluster organization supporting biotech innovation. Provided m4 Award funding in 2019 for early research.
  • EIT Health EUminorStrategic or Co-development PartnerEuropean health innovation community providing support and resources for healthcare innovation across Europe.
  • Plectonic Logibody GmbHcoreStrategic or Co-development PartnerAffiliated entity executing research on LOGIBODY technology. Company founded as spin-off with research executed through this partner organization.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Plectonic Biotech competitors and assessment

Company assessment

Direct peers

  • Adagene: Adagene uses AI-driven antibody discovery and engineering to develop precision antibodies including conditionally activated formats. The company represents a peer in next-generation antibody engineering combining computational approaches with novel antibody architectures, paralleling Plectonic's LOGIBODY + Sonrai AI strategy.
  • Numab Therapeutics: Numab develops multispecific antibodies using its proprietary lambda-cap and Fv-Ig formats that combine multiple binding specificities in single molecules. Both companies engineer multi-specificity antibody constructs designed to achieve selective biological function through combinatorial antigen recognition.
  • BioAtla: BioAtla develops Conditionally Active Biologics (CABs), which are antibodies and other proteins engineered to activate selectively in the tumor microenvironment using a similar logic-gated mechanism to LOGIBODY. Both companies are pursuing the same strategic thesis: that conditional, tumor-restricted activation can overcome the safety ceiling of conventional antibody therapies.
  • Molecular Partners: Molecular Partners develops DARPins (Designed Ankyrin Repeat Proteins), a non-antibody scaffold alternative to traditional monoclonal antibodies for therapeutic applications. Both companies engineer novel protein scaffolds as alternatives to conventional antibodies, pursuing similar therapeutic goals through different structural approaches.
  • Maverick Therapeutics (Takeda): Maverick developed logic-gated T-cell engagers designed to activate only when both a tumor antigen and a second contextual marker are detected — directly analogous to Plectonic's LOGIBODY mechanism. Acquired by Takeda in 2021, Maverick represents the most direct mechanistic parallel in oncology immunotherapy.
  • CytomX Therapeutics: CytomX's Probody platform uses conditionally activated antibodies that are masked until activated by tumor-associated proteases — conceptually the closest commercial-stage analogue to Plectonic's logic-gated LOGIBODY approach. Both companies target the same unmet need of reducing on-target/off-tumor toxicity in antibody therapeutics.
  • Crescendo Biologics: Crescendo Biologics develops T-cell engagers based on a proprietary Humabody VH domain platform — a non-standard antibody scaffold for engaging immune cells against tumors. Both companies pursue T-cell-engaging therapeutics using novel protein scaffolds as alternatives to conventional bispecific antibodies.

Broad incumbents

  • Philogen: Philogen develops antibody-based therapeutics for oncology and inflammatory diseases, including antibody-cytokine fusion proteins and targeted immunocytokines. As a European clinical-stage antibody therapeutics company, Philogen represents both a comparable regional player and a potential strategic partner for Plectonic's T-cell engaging platform.
  • Genmab: Genmab is the leading independent bispecific antibody company with its Duobody platform, generating products like epcoritamab. As the established leader in bispecific antibody engineering for oncology, Genmab represents both a potential partner and the competitive benchmark that any next-generation bispecific or logic-gated platform must outperform.

Emerging players

  • Cullinan Oncology: Cullinan Oncology is a clinical-stage biopharmaceutical company developing a diversified pipeline of oncology therapeutics including T-cell engagers and bispecific antibodies. Both companies pursue multi-program oncology strategies targeting immune engagement with novel modalities, though Cullinan is several years ahead clinically.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Plectonic Biotech social profiles

Digital presence

Plectonic Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Plectonic Biotech leadership team

Management profile

Number of profiles

Profiles10 records

Plectonic Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Plectonic Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plectonic Biotech

What does Plectonic Biotech do?

Plectonic Biotech develops the LOGIBODY Technology Platform, a DNA nanotechnology-based immunotherapy platform for targeted cancer therapy. LOGIBODYs are logic-gated antibodies built on DNA nanostructure scaffolds that selectively activate immune cells only when a specific tumor antigen pattern is detected, combining antibody specificity with DNA-based structural stability and modularity. The platform is being advanced through preclinical development for two undisclosed oncology indications with potential expansion into autoimmune disease applications.

Is Plectonic Biotech a public or private company?

Plectonic Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Plectonic Biotech founded?

Plectonic Biotech was founded in 2023. It employs 11 to 50 people.

Where is Plectonic Biotech based?

Plectonic Biotech is headquartered in Munich, Germany, in the Europe region.

Who are Plectonic Biotech's main competitors?

Direct peers on record are Adagene, Numab Therapeutics, BioAtla, Molecular Partners, Maverick Therapeutics (Takeda), CytomX Therapeutics and Crescendo Biologics. Broad incumbents are Philogen and Genmab. Cullinan Oncology is listed as an emerging player.

Does Plectonic Biotech have an API?

No public API is recorded for Plectonic Biotech.

What industry is Plectonic Biotech in?

Plectonic Biotech's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals